Compare · BSX vs LMAT
BSX vs LMAT
Side-by-side comparison of Boston Scientific Corporation (BSX) and LeMaitre Vascular Inc. (LMAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and LMAT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.16B, about 33.4x LMAT ($2.16B).
- Over the past year, BSX is down 51.6% and LMAT is up 13.0% - LMAT leads by 64.6 points.
- Both names hit the wire about 12 times in the past 4 weeks.
- BSX has more recent analyst coverage (25 ratings vs 16 for LMAT).
- Company
- Boston Scientific Corporation
- LeMaitre Vascular Inc.
- Price
- $48.48-0.16%
- $94.08+0.58%
- Market cap
- $72.16B
- $2.16B
- 1M return
- -14.40%
- -14.30%
- 1Y return
- -51.59%
- +13.01%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2006
- News (4w)
- 12
- 12
- Recent ratings
- 25
- 16
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
LeMaitre Vascular Inc.
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes, which cut valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular patches, which are used for closure of vessels after surgical intervention; closure systems to attach vessels to one another with titanium clips instead of sutures; and surgical glue. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest LMAT
- SEC Form 4 filed by Director Jasinski Lawrence J
- SEC Form 4 filed by Director O'Connor John James
- SEC Form 4 filed by Director Roush John A
- SEC Form 4 filed by Director Shadan Martha
- SEC Form 4 filed by Director Pellegrino Joseph P Jr
- SEC Form 4 filed by Chief Financial Officer Leblanc Dorian Paul
- SEC Form 4 filed by President and Director Roberts David B
- SEC Form 4 filed by Senior V. P., Operations Kamke Trent G
- Chairman and CEO Lemaitre George W gifted 11,974 shares and was granted 11,974 shares, decreasing direct ownership by 0.84% to 1,418,045 units (SEC Form 4)
- LeMaitre Vascular Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders